China's biopharmaceutical industry is undergoing a landmark transformation, emerging from a period of profound recalibration to establish itself as a global powerhouse. Propelled by its talent, patient access, cost-efficient infrastructure, and catalysed by comprehensive government policies aimed at supporting the innovative drug value chain, the sector is experiencing a broad-based resurgence, with results beginning to show in earnings and valuations in the first half of the year. The journey, however, is just beginning, fueled by the impending global patent cliff and its strong value proposition: delivering high-quality, innovative medicines at an accelerated pace. This capability ensures China's biopharma sector an indispensable player in the global market, even in the face of possible geopolitical headwinds. In this article, we discuss about the leading innovators in the homegrown biotech landscape—companies well-represented in our Premia China New Economy ETF (3173/9173 HK) and Premia China STAR50 ETF (3151/9151/83151 HK), which have outperformed multiple benchmarks year-to-date and will continue to drive alpha returns for global investors, propelled by a revaluation trend driven by domestic policy tailwinds, strong external partnerships and a rising market value.

Oct 03, 2025